SNTI
Senti Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.33
−2.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 55.0K | 22.0K | — | 2.0M | 3.3M |
| Cost of Revenue | 1.6M | 3.6M | — | — | — |
| Gross Profit | (1.5M) | (3.6M) | — | 2.0M | 3.3M |
| Operating Expenses | |||||
| R&D Expense | 31.3M | 37.6M | 34.4M | 32.1M | 28.1M |
| SG&A Expense | 24.1M | 26.2M | 23.5M | 34.9M | 37.6M |
| General & Admin Expense | 24.1M | 26.2M | 23.5M | 34.9M | 37.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (414.0K) | (3.6M) | 3.2M | 27.7M | (408.0K) |
| Total Operating Expenses | 55.0M | 60.1M | 61.0M | 94.7M | 65.4M |
| Cost and Expenses | 56.6M | 63.7M | 61.0M | 94.7M | 65.4M |
| Operating Income (EBIT) | (56.5M) | (63.7M) | (61.0M) | (92.7M) | (62.1M) |
| Non-Operating | |||||
| Interest Income | 419.0K | 927.0K | 948.0K | 2.9M | 1.7M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 419.0K | 927.0K | 948.0K | 2.9M | 1.7M |
| Other Non-Op Income/Expense | 7.0M | 2.3M | 8.2M | 9.3M | 12.4M |
| Non-Operating Income (excl Interest) | (6.4M) | (2.3M) | (313.0K) | (26.0M) | (12.4M) |
| EBT (Pre-Tax Income) | (49.6M) | (61.4M) | (52.8M) | (83.4M) | (49.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (49.6M) | (61.4M) | (52.8M) | (71.1M) | (58.2M) |
| Earnings from Cont. Ops | (49.6M) | (61.4M) | (52.8M) | (83.4M) | (49.7M) |
| Earnings from Discont. Ops | — | — | — | 12.3M | (8.5M) |
| Bottom Line Net Income | (49.6M) | (61.4M) | (52.8M) | (71.1M) | (58.2M) |
| Per Share | |||||
| Basic EPS | ($1.77) | ($2.73) | ($11.49) | ($20.94) | ($13.25) |
| Diluted EPS | ($1.77) | ($2.73) | ($11.49) | ($20.94) | ($13.25) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.45 | $0.75 |
| Shares | |||||
| Basic Shares Outstanding | 31.1M | 224.8M | 4.6M | 4.4M | 4.4M |
| Diluted Shares Outstanding | 31.1M | 224.8M | 4.6M | 4.4M | 4.4M |
| Profitability Metrics | |||||
| EBITDA | (47.2M) | (57.8M) | (54.9M) | (61.3M) | (45.7M) |
| D&A | 2.9M | 3.6M | 5.9M | 5.4M | 3.9M |
| EBIT | (50.1M) | (61.4M) | (60.7M) | (66.8M) | (49.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026